Bioventus (NASDAQ:BVS) Issues Quarterly Earnings Results

Bioventus (NASDAQ:BVS) posted its quarterly earnings data on Wednesday. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06, FiscalAI reports. The firm had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

• Strong Q1 results — revenue $132M (+7%), Adjusted EBITDA $24M (+24%), and Adjusted EPS $0.15 (nearly double); company raised 2026 Adjusted EPS and cash-from-operations guidance and reaffirmed revenue guidance of $600–$610M.
• The company is accelerating investment in four growth drivers (PNS, PRP, Ultrasonics, International), with PNS receiving more than half of planned spend and a dedicated general manager (Megan Rosengarten) hired to scale the PNS business.
• Cash generation and balance sheet progress — cash from operations increased by ~$28M YoY, debt was reduced by $22M to $272M, and management expects net leverage <2x by end of Q2 2026, prioritizing debt paydown and capital optionality.
• Margin and earnings resilience — adjusted gross margin of 76% (+110 bps) and adjusted EBITDA margin of 18% (+260 bps); management expects to hold ~20% adjusted EBITDA margin for 2026 despite stepped-up investments.
• Q1 benefited from a one-time favorable rebate adjustment (and ~+$2M FX tailwind); management calls the rebate timing idiosyncratic and did not raise full-year revenue guidance, signaling some of the quarter’s upside may not recur.

Bioventus Stock Performance

Bioventus stock traded down $0.14 during mid-day trading on Thursday, reaching $10.79. The company’s stock had a trading volume of 428,983 shares, compared to its average volume of 374,174. Bioventus has a 12-month low of $5.81 and a 12-month high of $11.25. The company has a market capitalization of $896.77 million, a P/E ratio of 32.85 and a beta of 0.72. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. The firm’s fifty day moving average price is $9.28 and its two-hundred day moving average price is $8.19.

Wall Street Analysts Forecast Growth

BVS has been the subject of several analyst reports. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Craig Hallum raised their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Barrington Research raised their price target on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. Finally, CJS Securities started coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Bioventus has an average rating of “Buy” and a consensus price target of $14.00.

Insiders Place Their Bets

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC grew its stake in Bioventus by 4.1% in the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock valued at $44,993,000 after buying an additional 236,741 shares in the last quarter. Vanguard Group Inc. grew its stake in Bioventus by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock valued at $19,567,000 after buying an additional 122,749 shares in the last quarter. Royce & Associates LP grew its stake in Bioventus by 15.6% in the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock valued at $8,449,000 after buying an additional 170,900 shares in the last quarter. Geode Capital Management LLC grew its stake in Bioventus by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock valued at $8,337,000 after buying an additional 19,388 shares in the last quarter. Finally, State Street Corp grew its stake in Bioventus by 1.7% in the 4th quarter. State Street Corp now owns 891,024 shares of the company’s stock valued at $6,629,000 after buying an additional 14,590 shares in the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus News Summary

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Q1 earnings beat: Bioventus reported EPS of $0.15 vs. the consensus $0.09 and revenue of $132.09M, a clear upside to street expectations that supports near‑term earnings momentum. Read More.
• Positive Sentiment: FY‑2026 EPS guidance in line to slightly above consensus: management set EPS guidance of $0.750–$0.790 (consensus ~$0.750), giving some visibility to full‑year profitability and validating the beat. Read More.
• Neutral Sentiment: Company disclosure and investor materials are available: earnings call transcript and slide deck provide management color on drivers and execution — useful for assessing sustainability of the beat. Read More. • Read More.
• Neutral Sentiment: Trading context: volume is roughly in line with average and the stock remains nearer its 52‑week high than low; investors should weigh one quarter’s beat against valuation (PE ~32.5). Read More.
• Negative Sentiment: Profitability and leverage are concerns: net margin was ~4.0% and debt‑to‑equity about 1.22 — modest margins and leverage limit upside unless revenue growth or margin expansion accelerates. Read More.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.